Thermo Fisher delivered a solid Q4 2025, reporting higher revenue and earnings per share, with strong net income. The company advanced its growth strategy through major product launches, AI collaborations, and strategic acquisitions.

Thermo Fisher Scientific delivered a strong third quarter in 2025, achieving a 5% increase in revenue to $11.12 billion and a 10% rise in adjusted diluted EPS to $5.79. The company demonstrated excellent operational performance, advanced its growth strategy with new product launches, strengthened its commercial engine, and successfully executed its capital deployment strategy through strategic acquisitions and stock repurchases.

Thermo Fisher Scientific delivered a strong second quarter in 2025, with revenue increasing by 3% to $10.85 billion and GAAP diluted EPS growing by 6% to $4.28. The company demonstrated excellent operational performance, driven by its PPI Business System, and continued to advance its growth strategy through innovation and strategic partnerships, despite a slight dip in adjusted EPS.

Thermo Fisher delivered a strong Q1 with slight revenue growth, improved GAAP EPS, and robust product innovation in semiconductor and precision medicine sectors.

Thermo Fisher Scientific reported a 5% increase in revenue to $11.40 billion for the fourth quarter of 2024. GAAP diluted EPS grew by 14% to $4.78, and adjusted EPS grew by 8% to $6.10. The company highlighted its focus on strengthening industry leadership and executing its capital deployment strategy.

Thermo Fisher Scientific reported third-quarter revenue of $10.60 billion and GAAP diluted EPS of $4.25. The company is raising its full-year adjusted EPS guidance to a new range of $21.35 to $22.07.

Thermo Fisher Scientific reported a revenue of $10.54 billion for the second quarter of 2024. GAAP diluted EPS increased by 15% to $4.04, and adjusted EPS increased by 4% to $5.37. The company is raising its full-year revenue and adjusted EPS guidance.

Thermo Fisher Scientific reported a revenue decline of 3% to $10.34 billion. GAAP diluted EPS increased 4% to $3.46, and adjusted EPS increased 2% to $5.11. The company is raising its full year revenue and adjusted EPS guidance to reflect stronger operational performance.

Thermo Fisher Scientific's fourth-quarter revenue reached $10.89 billion, a 5% decrease compared to the previous year, with a core organic revenue decline of 4%. Despite the revenue dip, the company's GAAP diluted EPS rose to $4.20, and adjusted EPS increased to $5.67, both marking a 5% increase year-over-year, driven by operating margin expansion.

Thermo Fisher Scientific reported a slight decrease in revenue for Q3 2023, but demonstrated strong earnings per share (EPS) growth. The company is managing macroeconomic challenges through its PPI Business System and continues to invest in future growth, including the acquisition of Olink Holding AB.

Thermo Fisher Scientific reported a 3% decrease in revenue to $10.69 billion compared to the same quarter last year, with core organic revenue growth of 2%. GAAP diluted EPS was $3.51, and adjusted EPS was $5.15. The company revised its full-year guidance due to a challenging macroeconomic environment.

Thermo Fisher Scientific reported a revenue of $10.71 billion, a 9% decrease compared to the same quarter last year. Core organic revenue growth was 6%. GAAP EPS was $3.32, and adjusted EPS was $5.03. The company launched innovative products, strengthened partnerships, and progressed towards renewable energy goals.

Thermo Fisher Scientific reported strong fourth-quarter results, with revenue growing 7% to $11.45 billion and adjusted EPS reaching $5.40. The company highlighted its continued investment in innovation and capacity expansion, as well as its progress on ESG priorities.

Thermo Fisher Scientific reported strong financial results for the third quarter of 2022. Revenue grew 14% to $10.68 billion, with a Core organic revenue growth of 14%. GAAP diluted EPS was $3.79, and adjusted EPS was $5.08. The company launched innovative new products and expanded capacity with new facilities.

Thermo Fisher Scientific reported second quarter revenue of $10.97 billion, an 18% increase year-over-year. GAAP diluted EPS was $4.22, while adjusted EPS was $5.51. The company highlighted its strong financial performance and strategic investments.

Thermo Fisher Scientific reported a 19% increase in revenue to $11.82 billion for the first quarter of 2022. The company's GAAP diluted EPS was $5.61, and adjusted EPS was $7.25. Core organic growth reached 16%, driven by strong performance in the PPD clinical research business and COVID-19 testing revenue of $1.68 billion.

Thermo Fisher Scientific reported fourth-quarter revenue of $10.70 billion, a 1% increase compared to the same quarter last year. The company's GAAP diluted EPS was $4.17, while adjusted EPS was $6.54.

Thermo Fisher Scientific reported a 9% increase in revenue to $9.33 billion for the third quarter of 2021. GAAP diluted EPS was $4.79, and adjusted EPS was $5.76. The company is raising its 2021 revenue and earnings guidance.

Thermo Fisher Scientific reported a strong second quarter with a 34% increase in revenue to $9.27 billion and a 44% increase in adjusted EPS to $5.60. The company also raised its full-year revenue and adjusted EPS guidance.

Thermo Fisher Scientific reported a strong first quarter in 2021, with revenue increasing by 59% to $9.91 billion and GAAP diluted EPS increasing by 198% to $5.88. The company's performance was driven by its role in enabling the COVID-19 response and accelerated growth in the base business. They also announced an agreement to acquire PPD, Inc. after the quarter end.

Thermo Fisher Scientific Inc. reported a significant increase in its financial performance for the fourth quarter and full year ended December 31, 2020. The company's fourth-quarter revenue grew by 54% to $10.55 billion, with GAAP diluted EPS increasing by 151% to $6.24 and adjusted EPS increasing by 100% to $7.09.

Thermo Fisher Scientific reported a strong third quarter in 2020, with revenue increasing by 36% to $8.52 billion and adjusted EPS increasing by 91% to $5.63. The company benefited from $2.0 billion in COVID-19 related revenue and growth in its base business.

Thermo Fisher Scientific's second quarter revenue increased by 10% to $6.92 billion, driven by strong demand for COVID-19 related products and services. Adjusted EPS increased 28% to $3.89.

Thermo Fisher Scientific's first quarter revenue increased by 2% to $6.23 billion. GAAP diluted EPS decreased by 2% to $1.97, while adjusted EPS increased by 5% to $2.94.

Thermo Fisher Scientific reported a 5% increase in revenue to $6.83 billion for the fourth quarter of 2019. GAAP diluted EPS increased by 12% to $2.49, and adjusted EPS increased by 9% to $3.55. The company saw growth across all segments, driven by innovation and strategic acquisitions.